Based in Paris, France, Scient’x, S.A. is a global medical device company that designs and develops surgical implants for the degenerative spine. Scient’x is the largest independent spine company outside of the Untied States. Its international distribution network consists of worldwide distributors in over 50 countries and has a direct sales force in France, Italy and the U.K. The Scient’x global surgeon education and training network augments its global distribution capabilities.

Core to the Company’s 20 year history of success in spine are differentiated products, notably posterior dynamic stabilization and cervical disc arthroplasty. Two flagship products are the Isobar® TTL semi-rigid rod which has been implanted in over 7,000 patients worldwide and the Discocerv® ceramic cervical disc which has been implanted in over 3,000 patients worldwide. The Isobar® is 510(k) cleared by the FDA in the United States as an adjunct to fusion.

http://www.scientx.com

Alphatec Spine, Inc. is one of the largest independent developers and manufacturers of implants for the surgical treatment of spine disorders. The company is primarily focused on the aging spine which allows it to use its broad product portfolio and pipeline to addresses one of the highest growth sectors in the orthopedics and spine industry. Alphatec’s product offering includes cervical, thoracolumbar, intervertebral, minimally invasive, vertebral compression fracture and allograft implants. In addition to itsU.S. operations, Alphatec markets a range of spine and orthopedic products in Asia through its subsidiary, Alphatec Pacific, Inc. and in Europe through a distribution network. Since the firm's March 2005 acquisition, Alphatec has attracted world-class management talent, expanded its infrastructure and manufacturing capabilities and grown revenues organically by a factor of seven from $17Mto $130M. In June 2006, Alphatec completed an $84 million initial public offering, and the Company raised an additional $32 million through a subsequent public offering in September 2007 and $10million in June 2009 through a PIPE offering.

NASDAQ: ATEC

http://www.alphatecspine.com

BioHorizons is positioned to become the leader in implant dentistry as the only company with a complete product offering, and it will soon become the first company in the industry to market and brand an integrated solution. The Company will leverage the digital technology experience at its dental laboratories to create a revolutionary business model in the industry, streamlining a highly fragmented process to create efficiency, cost savings, and superior patient outcomes. BioHorizons is headquartered in Birmingham, Alabama and has over 20 facilities worldwide. The senior management team has a combined 35 years of dental experience. They have successfully led and integrated 5 transactions at BioHorizons, which have increased headcount from 112 employees to more than 1,000.

http://www.biohorizons.com

Nexa Orthopedics, Inc. was founded in 2004 by HealthpointCapital to create the pre-eminent company in extremities surgery through a program of business investments, technology in-licensing, internal development and acquisition. The investment opportunity in the highly fragmented market was based on consolidation and scale, and driven by differentiated technology. In February 2005, Nexa acquired Futura Biomedical, LLC. Futura manufactured and distributed the only complete line of forefoot arthroplasty products and was a leading innovator of implants for the correction of flexible flatfoot deformities. In the summer of 2005, Nexa acquired the StayFuse™ product line from Pioneer Surgical. Nexa also partnered with OsteoBiologics, Inc. for US distribution of OBI products in hand, foot and ankle surgery. In November 2005, Nexa acquired BioProfile S.A., a French manufacturer of orthopedic extremity products utilizing its novel pyrocarbon. In September 2006, Nexa acquired Axiom orthopaedics, Inc., a leading innovator in the shoulder arthroplasty market.

HealthpointCapital Partners sold Nexa Orthopedics, Inc. to Tornier in February 2007. The sale of Nexa provided HealthpointCapital Partners, L.P. a 75% internal rate of return on its investment.

http://www.nexaortho.com/